Health Economics›Non-small cell lung cancer›Maintenance after first-line therapy

Maintenance after first-line therapy

Non-small cell lung cancer · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab monotherapy Variant #01	—	R 786 153	84d	~3.8 mo	~14.2 mo	~2	~R 1 572 306 PFS proxy · indirect	11
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~8.4 mo	~21.9 mo	~52	~R 14 921 674 PFS proxy · indirect	11
Sunitinib monotherapy Variant #01	—	R 33 433	42d	4.3 mo	—	2	R 49 300 PFS proxy	1
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	3.7 mo	—	2	R 38 164 PFS proxy	1
Erlotinib monotherapy Variant #01	—	R 13 907	28d	2.9 mo	—	2	R 27 814 PFS proxy	2
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	4.3 mo	13.4 mo	9	R 119 025 PFS proxy	2
Gefitinib monotherapy Variant #01	—	R 4 278	28d	4.8 mo	10.9 mo	2	R 8 556 PFS proxy	2
Docetaxel monotherapy Variant #02	—	R 2 921	28d	5.8 mo	—	9	R 26 293 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	3.8 mo	—	7	R 11 705 PFS proxy	1
Observation Partial	—	—	—	3.0 mo	—	—	—	1
Placebo Partial	—	—	—	2.6 mo	11.5 mo	—	—	14

11 of 11 regimens shown